Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (DE:EWL)
XETRA:EWL
Edwards Lifesciences (EWL) Stock Price & Analysis
2 Followers
EWL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€57.38 - €88.64
Previous Close€80.3
Volume156.00
Average Volume (3M)355.00
Market Cap
€47.41B
Enterprise Value€46.59B
Total Cash (Recent Filing)$1.64B
Total Debt (Recent Filing)$694.90M
Price to Earnings (P/E)37.4
Beta0.63
Next Earnings
Jul 25, 2024EPS Estimate
€0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.15
Shares Outstanding602,600,000
10 Day Avg. Volume278
30 Day Avg. Volume355
Standard Deviation0.08
R-Squared0.01
Alpha0.00971
Financial Highlights & Ratios
Price to Book (P/B)10.27
Price to Sales (P/S)8.06
Price to Cash Flow (P/CF)115.50
P/FCF Ratio240.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.76
Enterprise Value/Gross Profit10.07
Enterprise Value/Ebitda26.21
Forecast
1Y Price Target
€89.41Price Target Upside11.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Financial Guidance And PerformanceManagement's increased confidence in achieving the upper end of the full-year revenue guidance underscores the company's strong financial performance and growth prospects.
Market Share And Growth StrategyThe S3UR launch aims to regain market share in Europe, coupled with improved growth in Japan, highlighting strategic moves to bolster the company's market position.
Product Launch And Market OpportunityThe successful launch of the Evoque TTVR system, as the first commercially available transcatheter tricuspid valve platform in the US, taps into a significant market opportunity potentially exceeding $1B.
Bears Say
Financial PerformanceHigher than expected SG&A drove a ~180bp operating margin miss, which may be viewed critically by some investors.
Product PerformanceSmart trial reported a 20% paravalvular leak rate for Sapien 3, which is higher than the 10-12% rates observed in real-world registries such as the TVT registry.
Regulatory ChallengesBSX no longer expects FDA approval in 2024; management suspended enrollment in the single arm continued access study.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.06% Insiders
22.84% Mutual Funds
24.40% Other Institutional Investors
51.70% Public Companies and
Individual Investors
EWL FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was €57.38 and its highest was €88.64 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 25, 2024 which is in 83 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 25, 2024. The company reported €0.616 earnings per share for the quarter, beating the consensus estimate of €0.6 by €0.016.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is €0.65.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 602,600,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of €0.616 in its last earnings report, beating expectations of €0.6. Following the earnings report the stock price went down -0.807%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 544M.
---
Edwards Lifesciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€89.41 (11.34% Upside)
€89.41 (11.34% Upside)
Blogger Sentiment
Bullish
DE:EWL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $6.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.71%
12-Months-Change
Fundamentals
Return on Equity
21.59%
Trailing 12-Months
Asset Growth
12.54%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EWL Earnings Call
Q1 2024
0:00 / 0:00
---
EWL Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
EWL Stock 12 Months Forecast
Average Price Target
€89.41
▲(11.34% Upside)
Technical Analysis
Edwards Lifesciences
―
Boston Scientific
―
Medtronic
―
Integra Lifesciences
―
Becton Dickinson
―
Best Analysts Covering EWL
1 Year
1 Year Success Rate
23/32 ratings generated profit
1 Year Average Return
+18.64%
reiterated a buy rating 23 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 71.88% of your transactions generating a profit, with an average return of +18.64% per trade.
---